60 related articles for article (PubMed ID: 23311753)
1. The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
Kaiser MF; Heider U; Mieth M; Zang C; von Metzler I; Sezer O
Eur J Haematol; 2013 Apr; 90(4):263-72. PubMed ID: 23311753
[TBL] [Abstract][Full Text] [Related]
2. Bone building with bortezomib.
Roodman GD
J Clin Invest; 2008 Feb; 118(2):462-4. PubMed ID: 18219395
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and clinical outcomes of vitamin D deficiency among Japanese multiple myeloma patients: a single-center observational study.
Isoda A; Miyazawa Y; Ishikawa T; Kanaya S; Nakayama K; Mihara M; Iriuchishima H; Saito A; Matsumoto M; Sawamura M
Support Care Cancer; 2023 Sep; 31(9):547. PubMed ID: 37656213
[TBL] [Abstract][Full Text] [Related]
4. Preventing osteolytic lesions and osteomyelitis in multiple myeloma.
Dao A; McDonald MM; Savage PB; Little DG; Schindeler A
J Bone Oncol; 2022 Dec; 37():100460. PubMed ID: 36388641
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D as a Potential Player in Immunologic Control over Multiple Myeloma Cells: Implications for Adjuvant Therapies.
Kulig P; Łuczkowska K; Bielikowicz A; Zdrojewska D; Baumert B; Machaliński B
Nutrients; 2022 Apr; 14(9):. PubMed ID: 35565770
[TBL] [Abstract][Full Text] [Related]
6. Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies.
Innao V; Allegra A; Ginaldi L; Pioggia G; De Martinis M; Musolino C; Gangemi S
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066482
[TBL] [Abstract][Full Text] [Related]
7. A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche.
Solimando AG; Vacca A; Ribatti D
J Oncol; 2020; 2020():6820241. PubMed ID: 32508920
[TBL] [Abstract][Full Text] [Related]
8. A retrospective analysis of the prevalence and clinical outcomes of vitamin D deficiency in myeloma patients in tropical Australia.
Nath K; Ganeshalingam V; Ewart B; Heyer E; Watt K; Birchley A; Casey J; Lai HC; Morris E; Hodges G
Support Care Cancer; 2020 Mar; 28(3):1249-1254. PubMed ID: 31227990
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D in prostate cancer.
Trump DL; Aragon-Ching JB
Asian J Androl; 2018; 20(3):244-252. PubMed ID: 29667615
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?
Xu S; De Veirman K; De Becker A; Vanderkerken K; Van Riet I
Leukemia; 2018 Jul; 32(7):1500-1514. PubMed ID: 29535427
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib prevents ovariectomy-induced osteoporosis in mice by inhibiting osteoclast differentiation.
Kim SH; Kim MO; Kim HJ; Neupane S; Kim HJ; Lee JH; Kim HH; Kim JY; Lee Y
J Bone Miner Metab; 2018 Sep; 36(5):537-546. PubMed ID: 29027021
[TBL] [Abstract][Full Text] [Related]
12. The effects of proteasome inhibitors on bone remodeling in multiple myeloma.
Zangari M; Suva LJ
Bone; 2016 May; 86():131-8. PubMed ID: 26947893
[TBL] [Abstract][Full Text] [Related]
13. Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
Wang J; Udd KA; Vidisheva A; Swift RA; Spektor TM; Bravin E; Ibrahim E; Treisman J; Masri M; Berenson JR
Support Care Cancer; 2016 Jul; 24(7):3105-10. PubMed ID: 26902977
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.
Accardi F; Toscani D; Bolzoni M; Dalla Palma B; Aversa F; Giuliani N
Biomed Res Int; 2015; 2015():172458. PubMed ID: 26579531
[TBL] [Abstract][Full Text] [Related]
15. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Dou QP; Zonder JA
Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stem cell contact promotes CCN1 splicing and transcription in myeloma cells.
Dotterweich J; Ebert R; Kraus S; Tower RJ; Jakob F; Schütze N
Cell Commun Signal; 2014 Jun; 12():36. PubMed ID: 24965524
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D up-regulates the vitamin D receptor by protecting it from proteasomal degradation in human CD4+ T cells.
Kongsbak M; von Essen MR; Boding L; Levring TB; Schjerling P; Lauritsen JP; Woetmann A; Ødum N; Bonefeld CM; Geisler C
PLoS One; 2014; 9(5):e96695. PubMed ID: 24792400
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvement.
Tosi P
Scientifica (Cairo); 2013; 2013():104546. PubMed ID: 24381787
[TBL] [Abstract][Full Text] [Related]
19. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
[TBL] [Abstract][Full Text] [Related]
20. The role of vitamin D in hematologic disease and stem cell transplantation.
Hall AC; Juckett MB
Nutrients; 2013 Jun; 5(6):2206-21. PubMed ID: 23778150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
